FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947666474> ?p ?o ?g. }

• W2947666474 endingPage "e14087" @default.
• W2947666474 startingPage "e14087" @default.
• W2947666474 abstract "e14087 Background: Immune-related adverse events (irAEs) have been shown to be associated with the efficacy of immune checkpoint inhibitors in patients with advanced cancer, but the reported effect sizes have varied greatly in previous trials. We did a meta-analysis to assess immune checkpoint inhibitors efficacy and further explored the correlation of irAEs with efficacy in cancer. Methods: We systematically searched database inception to January, 2019 for randomized trials of immune checkpoint inhibitor in patients with advanced cancer that had available data for overall survival (OS) and progression-free survival (PFS), and irAEs. We calculated the pooled hazard ratios (HRs) and 95% confidence intervals [CIs] using a random-effects model, and assessed the association between the irAEs and PFS or OS using coefficient of determination ( R²). The PROSPERO registry number is CRD42017075610. Results: Thirty eight trials with 19,521 patients were included. Compared with conventional therapy, anti-PD-1 or PD-L1 combined with conventional therapy significantly enhanced survival (HR = 0.62, 95% CI 0.53 to 0.72 for PFS; HR = 0.71, 95% CI 0.58 to 0.87 for OS), and anti-PD1 or PD-L1 combined with anti-CTLA4 (HR = 0.75, 95% CI 0.63 to 0.90 for PFS). Anti-CTLA4 plus conventional therapy prolonged PFS (HR = 0.80, 95% CI 0.72 to 0.89) and OS (HR = 0.80, 95% CI 0.66 to 0.96) than conventional therapy alone. Anti-PD1 or PD-L1 outperformed anti-CTLA4 on OS (HR = 0.68, 95% CI 0.57 to 0.81). Significant correlation between treatment efficacy and irAEs was only identified in pneumonitis ( R 2 0.59, P = 0.026 for PFS) and diarrhea ( R 2 0.22, P = 0.006 for OS). Conclusions: We recommended the concurrent use of immune checkpoint inhibitor and conventional therapy or dual immunotherapy as the most appropriate regimens for advanced cancer. Furthermore, development of pneumonitis and diarrhea were associated with survival outcome of immune checkpoint inhibitors in patients with advanced cancer." @default.
• W2947666474 created "2019-06-07" @default.
• W2947666474 creator A5003217656 @default.
• W2947666474 creator A5016101422 @default.
• W2947666474 creator A5039969636 @default.
• W2947666474 creator A5060987863 @default.
• W2947666474 creator A5061274135 @default.
• W2947666474 creator A5062737889 @default.
• W2947666474 creator A5064188865 @default.
• W2947666474 creator A5090223092 @default.
• W2947666474 date "2019-05-20" @default.
• W2947666474 modified "2023-10-16" @default.
• W2947666474 title "Association of immune-related adverse events with immune checkpoint inhibitor efficacy in pancancer." @default.
• W2947666474 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e14087" @default.
• W2947666474 hasPublicationYear "2019" @default.
• W2947666474 type Work @default.
• W2947666474 sameAs 2947666474 @default.
• W2947666474 citedByCount "1" @default.
• W2947666474 countsByYear W29476664742020 @default.
• W2947666474 crossrefType "journal-article" @default.
• W2947666474 hasAuthorship W2947666474A5003217656 @default.
• W2947666474 hasAuthorship W2947666474A5016101422 @default.
• W2947666474 hasAuthorship W2947666474A5039969636 @default.
• W2947666474 hasAuthorship W2947666474A5060987863 @default.
• W2947666474 hasAuthorship W2947666474A5061274135 @default.
• W2947666474 hasAuthorship W2947666474A5062737889 @default.
• W2947666474 hasAuthorship W2947666474A5064188865 @default.
• W2947666474 hasAuthorship W2947666474A5090223092 @default.
• W2947666474 hasConcept C121608353 @default.
• W2947666474 hasConcept C126322002 @default.
• W2947666474 hasConcept C143998085 @default.
• W2947666474 hasConcept C197934379 @default.
• W2947666474 hasConcept C203014093 @default.
• W2947666474 hasConcept C207103383 @default.
• W2947666474 hasConcept C2777701055 @default.
• W2947666474 hasConcept C2780851360 @default.
• W2947666474 hasConcept C44249647 @default.
• W2947666474 hasConcept C71924100 @default.
• W2947666474 hasConcept C8891405 @default.
• W2947666474 hasConceptScore W2947666474C121608353 @default.
• W2947666474 hasConceptScore W2947666474C126322002 @default.
• W2947666474 hasConceptScore W2947666474C143998085 @default.
• W2947666474 hasConceptScore W2947666474C197934379 @default.
• W2947666474 hasConceptScore W2947666474C203014093 @default.
• W2947666474 hasConceptScore W2947666474C207103383 @default.
• W2947666474 hasConceptScore W2947666474C2777701055 @default.
• W2947666474 hasConceptScore W2947666474C2780851360 @default.
• W2947666474 hasConceptScore W2947666474C44249647 @default.
• W2947666474 hasConceptScore W2947666474C71924100 @default.
• W2947666474 hasConceptScore W2947666474C8891405 @default.
• W2947666474 hasIssue "15_suppl" @default.
• W2947666474 hasLocation W29476664741 @default.
• W2947666474 hasOpenAccess W2947666474 @default.
• W2947666474 hasPrimaryLocation W29476664741 @default.
• W2947666474 hasRelatedWork W1900595920 @default.
• W2947666474 hasRelatedWork W2114624491 @default.
• W2947666474 hasRelatedWork W2154948599 @default.
• W2947666474 hasRelatedWork W2194631636 @default.
• W2947666474 hasRelatedWork W2793335702 @default.
• W2947666474 hasRelatedWork W2889691785 @default.
• W2947666474 hasRelatedWork W2913113213 @default.
• W2947666474 hasRelatedWork W3022645438 @default.
• W2947666474 hasRelatedWork W4210646467 @default.
• W2947666474 hasRelatedWork W4254083861 @default.
• W2947666474 hasVolume "37" @default.
• W2947666474 isParatext "false" @default.
• W2947666474 isRetracted "false" @default.
• W2947666474 magId "2947666474" @default.
• W2947666474 workType "article" @default.